The lack of association between angiotensin-converting enzyme gene insertion/deletion polymorphism and nicotine dependence in multiple sclerosis by Nadalin, Sergej et al.
Brain and Behavior 2017; 7: e00600; wileyonlinelibrary.com/journal/brb3
DOI: 10.1002/brb3.600
  |  1 of 7© 2016 The Authors. Brain and Behavior 
published by Wiley Periodicals, Inc.
Received: 17 June 2016  |  Revised: 14 September 2016  |  Accepted: 3 October 2016
DOI: 10.1002/brb3.600
Abstract
Objective: Blood- borne angiotensin II is generated from angiotensinogen via cleavage 
by renin and angiotensin- converting enzyme (ACE), an enzymatic cascade known as 
the renin–angiotensin system (RAS). Several lines of evidence indicate that ACE, be-
yond its classical role of mediating blood pressure regulation, might contribute to the 
etiology of substance addictions by influencing dopaminergic signaling. A functional 
insertion/deletion (I/D) polymorphism of the ACE gene was associated with risk for 
being a smoker among individuals with depression and with smoking severity in stud-
ies comprising patients with depression and healthy controls. Several reports have 
described significantly increased ACE activity in cerebrospinal fluid and serum among 
MS patients. Furthermore, in our previous work with MS patients from Croatian and 
Slovenian populations, we demonstrated that the ACE- I/D polymorphism contributes 
to an elevated MS risk among male patients. Here we investigated whether the ACE- 
I/D polymorphism might influence smoking behavior among patients with MS.
Patients and Methods: Genotyping was performed in 521 patients (males/females: 
139/382) using polymerase chain reaction.
Results: We revealed no significant differences in ACE genotype and allele frequen-
cies between smokers and nonsmokers and no significant association between the 
ACE- I/D polymorphism and either pack- year smoking history or number of cigarettes 
smoked daily (p > .05, respectively).
Conclusion: The ACE- I/D polymorphism does not contribute either to risk for nicotine 
dependence or to smoking severity among MS patients. In the context of reports on the 
ACE- I/D polymorphism and nicotine dependence among healthy controls and patients 
with depression, we may speculate that the mechanism by which this polymorphism in-
fluences nicotine dependence risk differs in MS compared to depression, although not 
compared to a healthy population. In addition to angiotensin II, other potential ACE sub-
strates, such as substance P and neurotensin, which also influence dopaminergic neuro-
transmission (and are proposed to be associated with MS), may deserve study in future.
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1  | INTRODUCTION
Multiple sclerosis (MS) is a chronic autoimmune disease of the central 
nervous system in which myelin auto- reactive targeting T- lymphocytes 
drive an inflammatory process, leading to destruction of the myelin 
sheath, axonal loss, and neuronal degeneration (Ferreira et al., 2014; 
Mandia et al., 2014). Like other autoimmune disorders, MS is consid-
ered to be triggered by environmental factors in individuals with a 
genetic predisposition, and smoking has been considered one of the 
most established environmental risk factors for this illness (Mandia 
et al., 2014; Ramanujam et al., 2015). The relative risk of developing 
MS among smokers is almost twice that of never- smokers, and pa-
tients with MS who smoke exhibit a more severe disease course and 
a faster disability progression rate (Correale & Farez, 2015; Fragoso, 
2014; Healy et al., 2009; Manouchehrinia et al., 2013; Zhang et al., 
2016).
Blood- borne angiotensin II is generated from angiotensinogen via 
cleavage by renin and angiotensin- converting enzyme (ACE), an enzy-
matic cascade known as the renin–angiotensin system (RAS) (Nawaz 
& Hasnain, 2008; Wosik et al., 2007). Several lines of evidence sug-
gest that RAS, beyond its classical function in mediating the regula-
tion of blood pressure, might act as an important determinant in the 
etiology of nicotine dependence by influencing dopaminergic signal-
ing (Jenkins, Mendelsohn, & Chai, 1997; Jenkins et al., 1996; Obata, 
Takahashi, Kashiwagi, & Kubota, 2008). As a neurotransmitter, angio-
tensin II interacts with dopamine in mesocorticolimbic areas, and ACE 
modulates dopamine turnover in the rat striatum (Jenkins et al., 1996, 
1997). In addition, decreased dopamine release in rat striatum has 
been reported in response to captopril and enalaprilat, antihyperten-
sive drugs that inhibit ACE activity (Obata et al., 2008).
Current data regarding RAS- related genes in the etiology of nico-
tine dependence are sparse (Baghai et al., 2008; Hubacek, Adamkova, 
Skodova, Lanska, & Poledne, 2004; Hubacek, Pitha, Skodova, & 
Poledne, 2001). A functional 287- nucleotide fragment insertion/
deletion (I/D) polymorphism in intron 16 of the ACE gene accounts 
for approximately 50% of ACE levels (Rigat et al., 1990), is the most 
studied RAS- related polymorphic variant, and is the only RAS- related 
polymorphism investigated in the etiology of nicotine dependence 
so far (Baghai et al., 2008; Hubacek et al., 2001, 2004). Although sig-
nificantly greater risk for being a smoker has been observed among 
ACE- DD homozygous individuals with depression in the German 
population (Baghai et al., 2008), studies comprising healthy subjects 
from the Czech Republic and German populations found no associ-
ation between the ACE- I/D polymorphism and smoking risk (Baghai 
et al., 2008; Hubacek et al., 2004). Furthermore, the ACE- I/D poly-
morphism has been identified as possibly underlying smoking sever-
ity; the ACE- DD homozygous genotype contributes to higher daily 
cigarette consumption among patients with depression as well as to 
greater pack- years of smoking history among healthy individuals in the 
German population (Baghai et al., 2008).
To date, several reports have described significantly increased 
ACE activity in cerebrospinal fluid and serum among patients with 
MS (Constantinescu, Goodman, Grossman, Mannon, & Cohen, 1997; 
Kawajiri et al., 2008; Schweisfurth, Schiöberg- Schiegnitz, Kuhn, & 
Parusel, 1987). Furthermore, in our previous work with MS patients 
from Croatian and Slovenian populations, we demonstrated that the 
homozygous ACE- DD genotype might contribute to an elevated MS 
risk among male patients (Lovrečić et al., 2006). In line with these find-
ings and according to the evidence suggesting the relevance of RAS in 
brain dopaminergic signaling (Jenkins et al., 1996, 1997; Obata et al., 
2008), in the current work we aimed to investigate whether the ACE- 
I/D polymorphic variant might influence smoking behavior among pa-
tients with MS. Although the detrimental effects of smoking in MS 
are well established (Ramanujam et al., 2015; Zhang et al., 2016) and 
genetics has been proposed to play a substantial role in vulnerability to 
smoking (Li, 2008), to the best of our knowledge, no studies elucidat-
ing the etiology of nicotine dependence in MS have been published.
2  | PATIENTS AND METHODS
2.1 | Study participants
Our study group consisted of 521 patients, all fulfilling Mc Donald’s 
criteria for MS (Polman et al., 2005) and all recruited by collaborating 
genetic and clinical centers from Croatia and Slovenia, which belong to 
the same geographic area where the populations share a similar eth-
nic background (Table 1) (Zupan, Vrabec, & Glavač, 2013). The course 
of MS was classified according to the clinical data (Lublin & Reingold, 
1996), and disease severity was estimated using the Expanded 
Disability Status Scale and Multiple Sclerosis Severity Score at the time 
when blood samples for genetics analysis were taken (Kurtzke, 1983; 
Roxburgh et al., 2005). Patients under treatment with ACE inhibitors 
were excluded from the study. Neurologists obtained information con-
cerning the patients’ smoking status via a questionnaire. Smokers were 
defined as individuals who smoked more than one cigarette a day, and 
had smoked for more than one year. Nonsmokers were defined as 
those who had smoked less than 100 cigarettes during their lifetime 
(Guo et al., 2007; de Leon & Diaz, 2005). The numbers of quitters, 
occasional smokers, ex- smokers and those who have been smoking 
for less than 1 year were too small for statistical analysis and were 
excluded from the study. To assess the severity of nicotine depend-
ence, patients were also asked for pack- year smoking history, which 
was calculated by number of cigarettes smoked per day × number of 
years smoked. The study was approved by the Ethics Committees of 
both genetic centers and conducted according to the ethical standards 
expressed in the latest version of the Declaration of Helsinki.
2.2 | Genotyping
Genomic DNA was extracted from whole blood using a FlexiGene 
DNA kit 250 (QIAGEN GmbH, Hilden, Germany) according to the 
manufacturer’s instructions. Genotyping was performed by polymer-
ase chain reaction (PCR) analysis using protocols previously described 
(Rigat et al., 1990). To exclude mistyping of the ACE- ID heterozygotes 
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as ACE- DD homozygotes, all ACE- DD genotype samples were addi-
tionally confirmed with insertion- specific PCR (Shanmugam, Sell, & 
Saha, 1993).
2.3 | Statistical analysis
The ACE genotype and allele distributions among smokers and non-
smokers, as well as observed and expected genotype proportions 
according to Hardy–Weinberg equilibrium, were compared by the chi- 
square (χ2) test. The relationship between pack- year smoking history 
and number of cigarettes smoked daily and ACE genotype was evalu-
ated using a one- way analysis of variance. Probability (p) values less 
than .05 (p < .05) were considered statistically significant. Statistical 
analyses were performed using Statistica for Windows, version 12.
3  | RESULTS
In line with gender- specific differences in the effect of the ACE- I/D 
polymorphism in various conditions and/or diseases, such as blood 
pressure (among healthy individuals) (Avila- Vanzzini et al., 2015), 
hypertension (Higaki et al., 2000; Sipahi, Budak, Şen, Ay1, & Şener, 
2006), schizophrenia (Mazaheri, 2015; Nadalin, Buretić- Tomljanović, 
Ristić, Jonovska, & Tomljanović, 2015; Nadalin et al., 2012), as well as 
MS (Lovrečić et al., 2006), and according to observations of gender–
gene interaction in risk for nicotine dependence in general population 
(Beuten, Payne, Ma, & Li, 2006; Beuten et al., 2005; Nedic et al., 2010; 
Tochigi et al., 2007) and specific diseases (i.e., schizophrenia) (Nadalin, 
Buretić- Tomljanović, Rebić, Pleša, & Šendula Jengić, 2016) association 
analyses between ACE- I/D polymorphism and smoking habits were 
performed separately among male and female patients. Furthermore, 
there is also evidence that estrogen may influence dopaminergic neu-
rotransmission, since it has been observed that estrogen treatment re-
duces dopamine receptor D2 levels in several rat brain regions (Chavez 
et al., 2010).
A slightly greater prevalence of nicotine dependence observed 
among male patients did not reach statistical significance (p > .05, re-
spectively); yet, data regarding smoking severity revealed significantly 
higher values of pack- year smoking history and a significantly greater 
number of cigarettes smoked per day among male patients compared 
to females with MS (p < .0001 in both cases, respectively) (Table 1). 
The prevalence of nicotine dependence was elevated when compared 
to the general Croatian and Slovenian populations (Klemenc- Ketiš & 
Kersnik, 2015; Loubeau, 2009; Turek et al., 2001). Table 2 shows the 
allele and genotype frequencies for the ACE- I/D polymorphism ac-
cording to patient smoking status. The statistical power of our study 
was 100% to detect a 1.5- fold increase in the ACE- D allele and ACE- I 
allele frequency, respectively. The ACE genotype distributions in 
male or female patients, as well as in male smokers or nonsmokers, 
and female smokers or nonsmokers, were consistent with the Hardy–
Weinberg equilibrium (p > .05, respectively). The ACE allele and gen-
otype frequencies were similar to those reported in our previous 
study (Lovrečić et al., 2006) and did not deviate from those observed 
in the European population (http://www.ncbi.nlm.nih.gov/snp/?ter-
m=rs1799752). No significant differences were found in ACE geno-
type and allele distributions between total male and female patients 
(p > .05, respectively). ACE genotype and allele frequencies between 
smokers and nonsmokers also did not differ significantly in male or 
female patients (p > .05, respectively), and no significant differences 
in frequencies of ACE genotype and alleles were detected when the 
TABLE  1 Characteristics of patients with multiple sclerosis
Males 
(n = 139)
Females 
(n = 382)
Age at onset 31.1 ± 8.7 31.4 ± 10.0
Age at blood sampling 44.1 ± 12.3 43.8 ± 12.0
Course (%)a
Primary progressive 18 (12.9) 26 (6.8)
Secondary progressive 45 (32.4) 95 (24.9)
Relapsing–remitting 76 (54.7) 261 (68.3)
Expanded Disability Status Scale 4.0 ± 2.5 3.6 ± 2.2
Multiple Sclerosis Severity Score 4.5 ± 2.9 4.2 ± 2.8
Smoking behavior
Smokers/nonsmokers 66/73 150/232
Pack- year smoking historyb 25.6 ± 17.3 14.2 ± 11.1
Number of cigarettes smoked per 
dayc
21.0 ± 7.6 14.6 ± 7.6
Males vs. Females: aχ2 = 9.6, p < .01; bF = 25.3, p < .0001; cF = 23.8, 
p < .0001.
TABLE  2 The frequency of ACE genotypes and alleles according to smoking status
Genotypes (%) Alleles (%)
DD ID II D I
Males Smokers (n = 66) 22 (33.3) 31 (47.0) 13 (19.7) 75 (56.8) 57 (43.2)
Nonsmokers (n = 73) 23 (31.5) 40 (54.8) 10 (13.7) 86 (58.9) 60 (41.1)
χ2 = 1.2, df = 2, p = .55 χ2 = 0.1, df = 1, p = .73
Females Smokers (n = 150) 44 (29.3) 78 (52.0) 28 (18.7) 166 (55.3) 134 (44.7)
Nonsmokers (n = 232) 61 (26.3) 127 (54.7) 44 (19.0) 249 (53.7) 215 (46.3)
χ2 = 0.4, df = 2, p = .80 χ2 = 0.2, df = 1, p = .65
ACE, angiotensin- converting enzyme.
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smokers (males vs. females) and nonsmokers (males vs. females) were 
analyzed separately. Finally, no significant association between the 
ACE- I/D polymorphism and either pack- year smoking history or num-
ber of cigarettes smoked daily was identified (p > .05, respectively) 
(Table 3).
4  | DISCUSSION
Components of cigarette smoke have been associated with demy-
elination and axonal degeneration, and nicotine compromises the 
blood–brain barrier and exerts immunomodulatory action on T- 
lymphocytes (Correale & Farez, 2015; Ramanujam et al., 2015; Zhang 
et al., 2016). In this study, which to our knowledge is the first to ad-
dress the genetics of nicotine dependence among patients with MS, 
we investigated whether smoking behavior in MS might be influenced 
by a functional ACE- I/D polymorphism that has proved to be relevant 
in both nicotine dependence and MS (Baghai et al., 2008; Lovrečić 
et al., 2006; Živković et al., 2016). In addition to our previous study 
that first identified the possible relevance of the ACE- I/D polymor-
phism in MS, only a few reports on the role of the ACE- I/D polymor-
phism in MS have been published so far (Hladikova, Vašků, Stourač, 
Benešová, & Bednařík, 2011; Klupka- Sarić et al., 2011; Živković et al., 
2016).
Since the homozygous ACE- DD genotype is associated with tis-
sue and plasma enzyme levels almost twice that of the homozygous 
ACE- II genotype (Rigat et al., 1990), we initially speculated that indi-
viduals with the ACE- DD genotype might release dopamine at higher 
levels and consequently could be more vulnerable to nicotine depen-
dence. However, our results demonstrating no significant influence 
of the ACE- I/D polymorphism on either smoking risk or the severity 
of nicotine dependence (Tables 2 and 3) do not argue in favor of our 
speculation. Our data are consistent with findings showing no asso-
ciation between the risk for nicotine dependence and the ACE- I/D 
polymorphism among healthy individuals from the Czech Republic 
and German populations (Baghai et al., 2008; Hubacek et al., 2004), 
as well as with a negative report on the association between this 
polymorphism and number of cigarettes smoked per week among 
healthy controls from the Czech Republic (Hubacek et al., 2004). 
However, the results are in disagreement with previous findings 
from a German population study reporting a positive association of 
ACE- DD homozygosity, nicotine dependence risk, and number of cig-
arettes smoked daily among patients with depression. They also are 
not in agreement with data showing a positive association between 
the ACE- DD homozygous genotype and pack- year smoking history 
among healthy individuals (Baghai et al., 2008). Thus, we may specu-
late that the plausible mechanism by which the ACE- I/D polymorphic 
variant contributes to risk for developing nicotine dependence differs 
in MS when compared with depression, although not when compared 
with a healthy population (Baghai et al., 2008; Hubacek et al., 2004). 
On the other hand, although the plausible mechanism by which the 
ACE- I/D polymorphism contributes to the severity of nicotine depen-
dence may also differ in MS when compared to depression (Baghai 
et al., 2008), whether it differs in comparison to a healthy popula-
tion is disputable because reports disagree about its influence on the 
number of cigarettes smoked per week and/or pack- year smoking 
history among healthy subjects (Baghai et al., 2008; Hubacek et al., 
2004). Finally, it is plausible that in addition to genetic factors, smok-
ing habits among patients with MS, in comparison to healthy controls, 
may be modified by the illness itself; for instance, because of indispo-
sition, patients with MS may smoke fewer cigarettes daily than before 
MS onset.
Advances in understanding of the RAS signaling pathway indicate 
an intriguing possibility that RAS, by modulating T- lymphocytes me-
diated autoimmunity, may be implicated in the detrimental effects 
of smoking in MS (Correale & Farez, 2015). Several studies have 
observed that angiotensin II promotes inflammation and tissue in-
jury, mediating key events in animal models of autoimmune disease 
(Marchesi, Paradis, & Schiffrin, 2008; Okunuki et al., 2009; Platten 
et al., 2009; Sagawa, Nagatani, Komagata, & Yamamoto, 2005; 
Stegbauer et al., 2009). Based on previous observations demon-
strating that serum ACE activity increases significantly after smok-
ing (Kitamura, 1987) and chronic smoking results in enhanced RAS 
activation in monozygotic twins, discordant for smoking (Laustiola, 
Lassila, & Nurmi, 1988), Correale and Farez (2015) (Correale & 
Farez, 2015) recently investigated whether RAS might be involved 
in immunomodulatory effects of smoking on MS progression. As ex-
pected, their findings argue in favor of smoking having modulator 
role in the expression and activity of RAS components: both auto- 
reactive T- lymphocytes and monocytes derived from patients who 
smoked produced significantly higher amounts of renin, ACE, as well 
as angiotensin II receptor type I (AT1R). Furthermore, they observed 
that inhibition of ACE using enalapril and blocking AT1R using anti-
hypertensive losartan, down- regulated interleukin (IL)- 17 and IL- 22 
secreting cell numbers in MS patients who smoked. In smokers, lo-
sartan treatment was associated with improvement of MS prognosis, 
ACE genotype
F pDD ID II
Pack- year smoking 
history
Males 26.8 ± 17.0 27.4 ± 18.5 19.9 ± 15.2 0.7 .50
Females 14.4 ± 9.3 14.0 ± 12.3 14.3 ± 10.2 0.0 .10
Number of cigarettes 
smoked per day
Males 21.6 ± 8.1 21.4 ± 6.4 19.2 ± 9.5 0.3 .71
Females 14.2 ± 7.4 14.8 ± 7.9 14.9 ± 7.3 0.1 .91
ACE, angiotensin- converting enzyme.
TABLE  3 The severity of nicotine 
dependence according to ACE- I/D 
polymorphism
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leading to a significant decrease in risk of conversion of clinically iso-
lated syndrome to definite MS.
Several limitations of this study should be noted here. Our sam-
ple included a relatively small number of participants, thus leaving 
open the possibility that some minor effects were not detected. 
In addition, it consisted of an unbalanced number of male and fe-
male patients, which might have led to bias in the statistical anal-
yses. Furthermore, the current sample also lacked a normal control 
group, and data regarding smoking behavior were based exclusively 
on patient self- report. For confirmation of these findings, further 
studies are required that include other diseases and/or conditions, 
assess nicotine dependence with more specific methods, such as the 
Fagerstrom test, and investigate the relevance of other RAS- related 
polymorphic variants in smoking behavior (e.g., those for angioten-
sinogen, angiotensin II receptors) (Hladikova et al., 2011; Živković 
et al., 2016). Moreover, because of a high prevalence of major de-
pressive disorder reported among MS patients (Siegert & Abernethy, 
2005) and in line with the positive association between smoking 
behavior and the ACE- I/D polymorphism among patients with de-
pression (Baghai et al., 2008), it would be interesting to investigate 
the relevance of the ACE- I/D polymorphism among those patients 
separately from other MS patients. Another issue that should be 
considered is that ACE, in addition to angiotensin II, has other po-
tential substrates, some of which influence dopaminergic neuro-
transmission (and are proposed to be associated with MS), such as 
substance P and neurotensin (Binder, Kinkead, Owens, & Nemeroff, 
2001; Krasnova, Bychkov, Lioudyno, Zubareva, & Dambinova, 2000; 
Soltys, Knight, Scharf, Pitt, & Mao- Draayer, 2014; Vilisaar et al., 
2015).
In conclusion, we report negative findings regarding the influence 
of the ACE- I/D polymorphism on smoking behavior among patients 
with MS. According to our results, this polymorphism does not con-
tribute either to risk for developing nicotine dependence or to smok-
ing severity in this patient group.
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